Piper Sandler raises UnitedHealth stock price target to $504

KeyBanc reiterated an Overweight rating on UnitedHealth (NYSE:UNH) with a $500 price target, citing undervaluation and strong Q3 results. The company reported $112.7B revenue, beating estimates, and raised its full-year EPS outlook to at least $20.50. Analysts highlight Medicare Advantage trends and midterm elections as potential catalysts.

Truist reiterated a Buy rating and $500 price target on UnitedHealth (UNH) after its Q3 results. UNH reported $112.7B revenue, beating estimates, and raised its 2026 EPS guidance to at least $20.50. The company's medical care ratio and operating cost ratio also exceeded expectations.

UnitedHealth Group (UNH) reported Q3 earnings of $4.69 per share, beating estimates of $4.14, and raised its annual profit outlook to at least $20.50 per share. Revenue was $112.69 billion, slightly above estimates but below last year's figure. The medical care ratio improved to 88.4%, indicating better profit margins. The stock has gained 20% over the past six months, with a current price of $378 and a price target of $481.

UnitedHealth (UNH) reported Q3 adjusted EPS of $4.69, beating estimates, and raised its 2026 outlook to at least $20.50. Revenue was $112.7bn, down from last year. Shares initially rose but closed 0.20% lower at $377.76. Cost control improved, with a lower medical-cost ratio. Mizuho maintained an outperform rating, citing margin recovery.

UnitedHealth Group (UNH) reported Q3 earnings exceeding expectations, with Optum Health showing operational improvements despite a 10% revenue decline. Optum Health CEO Patrick Conway outlined a multi-year path to 6%-8% margins, citing a shift to value-based care. UnitedHealth raised its 2026 adjusted earnings outlook to at least $20.50 per share. The company also introduced AI-powered Medicare Advantage plan recommendations and expects to cut prior authorizations by 30% by year-end.

UnitedHealth Group (UNH) reported Q3 results exceeding expectations, with adjusted EPS 13% above consensus and a medical loss ratio 150 bps better than anticipated. Mizuho Securities reaffirmed its 'outperform' rating, citing strong performance from UnitedHealthcare and OptumHealth, and highlighted the company's focus on sustaining profitability. Investors will watch for 2027 earnings growth outlook and operational updates.